uniQure N.V. research snapshot
QURE AI stock analysis currently reads uniQure N.V. as a high-risk, high-reward gene therapy biotechnology company with a potential near-term value inflection. The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close used here was $42.63, market capitalization was about $2.93 billion, and the main question was whether the AMT-130 Huntington disease BLA submission planned for Q3 2026 can lead to accelerated approval, and whether the company can commercialize Hemgenix while managing cash burn of roughly $209 million in trailing twelve months. This is informational research and not investment advice.
Current price
$42.63
Market cap
$2.93 billion
AI score
40 / 100
Rating
High-risk pre-commercial gene therapy company with major pipeline catalyst
Trend status
Strong YTD uptrend (+78%) after AMT-130 FDA meeting catalyst
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | uniQure is a gene therapy platform company with one approved product (Hemgenix for Hemophilia B) and a pipeline of CNS gene therapies. The business model is capital-intensive with binary pipeline risk. | Medium |
| Moat | The moat comes from proprietary gene therapy manufacturing know-how, AAV vector technology, and first-mover positioning in Huntington disease gene therapy. However, competitive gene therapy programs from other companies could narrow this advantage. | Low-medium |
| Management | Management has demonstrated ability to advance pipeline programs and secure regulatory meetings. The $225M upsized offering in June 2026 raised dilutive capital but extended the cash runway into late 2027. | Medium |
| Financial trend | Revenue from Hemgenix collaboration and commercial sales reached about $18M TTM, but the company remains deeply unprofitable with -$209M TTM net income and -$104M levered free cash flow. | Medium |
| Valuation | Standard valuation metrics are not meaningful for this pre-profit biotech. At $42.63, the market cap of $2.93B implies a significant pipeline premium. The cash-adjusted enterprise value is about $2.34B after subtracting $587M cash. | Low |
| Technical trend | QURE is in a strong uptrend after breaking above its 2025 highs. The stock has rallied from $8.73 low to $71.50 high over 52 weeks, then pulled back to $42.63. Barchart technical opinion rated the stock at 88% Buy. | Medium-high |
| Risk level | Key risks are clinical trial failure, regulatory rejection or delay for AMT-130, competitive gene therapy programs, dilutive share issuance, high cash burn rate, and the binary nature of pre-commercial biotech investing. | Medium-high |
| AI confidence | Medium confidence for business description, cash position, market pricing, and major risk categories. Lower confidence for future regulatory outcomes and pipeline valuation. | Medium data confidence |
| Investment certainty | Low certainty. uniQure is a high-risk biotech where investment outcome depends heavily on AMT-130 regulatory success, commercialization execution, and capital market conditions. | Low |
QURE AI stock forecast
The QURE AI stock forecast uses scenario ranges around the $42.63 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires AMT-130 accelerated approval and successful commercialization. The base case assumes AMT-130 BLA is accepted but faces a standard review timeline with questions. The bearish case assumes regulatory setbacks or clinical data disappointments.
$75 to $110
More likely if AMT-130 receives accelerated approval for Huntington disease with manageable label restrictions, Hemgenix revenue grows, and the company demonstrates a clear path to profitability. Analyst targets from HC Wainwright ($80) and average Street target ($64.70) support this zone.
$30 to $55
More likely if AMT-130 BLA is accepted and reviewed but the approval timeline extends beyond current expectations, requiring additional capital raises and causing the stock to trade range-bound between cash value and pipeline optionality.
$10 to $25
More likely if AMT-130 faces regulatory delays, requires additional clinical data, or shows safety/efficacy concerns. The stock could revert toward cash-adjusted value if the pipeline thesis weakens.
QURE AI technical analysis
QURE AI technical analysis starts from the $42.63 July 10 close used for this July 13 static page. Public technical sources showed the stock in a strong medium-term uptrend but significantly off its 52-week high of $71.50. Barchart rated the technical opinion at 88% Buy. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $42.63 | Latest verified close used for this page as of the July 13, 2026 data cutoff. |
| Near support | $39.00 to $40.82 | First and second support zones per Barchart key turning points. A hold above $40 keeps the near-term uptrend intact. |
| Secondary support | $36.99 | Third support level per Barchart. A break below would suggest the post-FDA meeting momentum has faded. |
| Near resistance | $44.65 to $46.66 | First and second resistance zones per Barchart. Reclaiming $44.65 would signal renewed buying interest. |
| Key resistance | $48.48 | Third resistance level. A breakout above this zone would target the 52-week high area. |
| 52-week range | $8.73 to $71.50 | The stock has a wide 52-week range, reflecting its binary biotech nature. The current price sits in the middle of this range. |
| Momentum | RSI near neutral, strong momentum over 6 months | The RSI was near neutral after the pullback from highs. The stock showed strong momentum over 6 months (+68%) and YTD (+78%). |
| Volume | About 1.1M shares daily avg | Volume was 1.14M on July 10, below the 2.2M average, suggesting the pullback may lack aggressive selling pressure. |
| Volatility | IV near 100%, HV 182% | Implied volatility near 100% and historical volatility of 182% underscore the extreme price risk. Position sizing must account for daily swings of $5-10. |
| Invalidation | Close below $37, then $26 | A close below $37 weakens the medium-term technical picture. A break below $26 (Fibonacci 38.2%) would challenge the bull thesis. |
QURE AI trading strategy
The QURE AI trading strategy is a rules-based framework, not personalized advice. It combines pipeline-stage evidence, technical confirmation, strict position sizing, and clear invalidation levels. Due to the extreme volatility and binary nature of biotech stocks, risk management is paramount.
Monitor for AMT-130 BLA submission (expected Q3 2026), FDA acceptance, priority review designation, and Advisory Committee dates. Price tends to move on regulatory news cycles.
Reduce position size before binary events. A failed BLA submission or clinical hold would likely cause a 40-60% drawdown.
If QURE pulls back toward $37 to $40 support without a fundamental thesis break, look for volume confirmation and technical stabilization before considering a position.
Biotech pullbacks can turn into structural declines. Never add to a position solely because the price dropped. Wait for fundamental catalyst confirmation.
Given the high volatility (IV near 100%, ATR likely $5-10), position sizing should be a fraction of what would be used for lower-volatility stocks. Define maximum loss before entry.
Use the $37 invalidation level and the $42 current price to define initial stop distance of roughly 13%. The extreme volatility means stops can be triggered by normal noise.
Investment research summary
uniQure develops one-time curative gene therapies for severe genetic diseases. Patients pay (or their insurers pay) for a single treatment that replaces or repairs the defective gene, creating a product revenue model with large per-patient pricing.
The moat is proprietary AAV-based gene therapy manufacturing expertise, IP around CNS delivery, and first-mover regulatory experience. Hemgenix was the first FDA-approved gene therapy for hemophilia B. Manufacturing know-how for AAV vectors at commercial scale creates a barrier for competitors.
The thesis can fail if AMT-130 misses efficacy endpoints or has safety issues in the ongoing Phase I/II, if the FDA requires a full Phase III before approval, if competitors develop better Huntington treatments, or if cash runs out before the pipeline generates meaningful revenue.
Management has progressed multiple gene therapy programs to clinical stages and secured regulatory alignment for accelerated approval. The June 2026 $225M offering was dilutive but strategically necessary to fund the AMT-130 BLA and commercial preparations.
Gene therapy represents a long-term secular shift in medicine, moving from symptom management to one-time curative treatments. CNS gene therapy for Huntington, ALS, and epilepsy addresses large unmet needs with limited current treatment options.
At $42.63 and a $2.93B market cap, with $587M cash and TTM revenue of only $18M, nearly all enterprise value is attributed to pipeline potential. The stock requires successful AMT-130 approval and commercial execution to justify the current price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| QURE price | $42.63 close on July 10, 2026 | Yahoo Finance and Barchart quote snapshots | July 13, 2026 |
| Market capitalization | $2.93B, verified as $42.63 x 68.75M shares | financial_rigor.py market cap verification and Yahoo Finance | July 13, 2026 |
| 52-week range | $8.73 to $71.50 | Yahoo Finance and Barchart | July 13, 2026 |
| TTM revenue | $18.09M (Yahoo), $16.1M (Barchart) | Yahoo Finance and Barchart; cross-validation showed 5.8% deviation between sources | July 13, 2026 |
| TTM net income | -$208.87M | Yahoo Finance financial summary | July 13, 2026 |
| Cash and cash equivalents | $586.55M (mrq) | Yahoo Finance balance sheet | July 13, 2026 |
| Public offering (June 2026) | $225M upsized offering, fully exercised | GlobeNewswire via Yahoo Finance | July 13, 2026 |
| Analyst consensus | Moderate Buy, 14 analysts, average target $64.70 | Yahoo Finance analyst page | July 13, 2026 |
| Barchart technical opinion | 88% Buy (Strong Buy) | Barchart technical analysis overview | July 13, 2026 |
| P/E (TTM) | N/A (negative earnings) | Yahoo Finance statistics | July 13, 2026 |
This QURE AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong. Biotech stocks carry elevated risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
